Scale -


  • Revenue is 5366 Rs Cr; Annual Growth is 20 %; in Top Quartile
  • Ebitda is 1205 Rs Cr; Annual Growth is 26 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 13 %
  • PBT is 240 Rs Cr; Annual Growth is 19 %; in Top Quartile
  • PAT is 595 Rs Cr; Annual Growth is 19 %; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Revenue is 1465 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile

Profitability -


  • PBDIT Margin is 22.46 %; Continuous Growth over 3 years

Return -


  • Asset Turnover is 77 %; in Top Quartile
  • ROCE is 16.15 %; Continuous Decline over 3 years

Efficiency -


  • Current Ratio is 1.8; Continuous Growth over 3 years
  • Quick Ratio is 1; Continuous Growth over 3 years
  • Inventory Turnover Ratio is 3.56; Continuous Growth over 3 years
  • Operating cash flow is 793 Rs Cr; in Top Quartile; 5 Year CAGR is 24 %

Solvancy -


  • Debt/Equity is 0.26; Continuous Decline over 3 years
  • Total Debt is 1338 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Long term Debt is 297 Rs Cr; in Top Quartile
  • Contingent Liabilities is 319 Rs Cr; in Top Quartile; 5 Year CAGR is 20 %

Quality -


  • Exceptional Items/PBT is -1 %; Annual Decline is -127 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is -5 %; Annual Decline is -24922 %; in Bottom Quartile
  • Current Tax/PAT is 33 %; Continuous Decline over 3 years
  • Operating cashflow/ebitda is 66 %; Annual Decline is -27 %
  • Operating cashflow/PAT is 133 %; Annual Decline is -23 %
  • Other Expenses/Total Expenses is 30 %; Continuous Growth over 3 years; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
From Rural Aspirations to Pharmaceutical Careers: Granules India’s Pharma Pathashala Creates Pathways for Youth
Granules India Allots 2.49 Crore Shares to Promoters Following Warrant Conversion
Granules India Details Preferential Allotment of 2.5 Crore Warrants to Promoters
Granules India promoter group stake rises to 37.39% after warrant conversion
Granules India promoter sells 1.72 crore shares in block deal
Granules India: ????????? ?? ???? ?? ???? ????, **2.5 ?????** ??????? ????
Granules India Mexico Subsidiary: GRANULES Expands Globally
Trade Spotlight: How should you trade Granules India, Federal Bank, Zydus Lifesciences, Firstsource Solutions, and others on October 23?
What Granules India Doubters Got Wrong
Granules India Gagillapur FDA Inspection and Manufacturing Compliance Explained
US FDA Starts Inspection at Granules India’s Telangana Plant
Granules India eyes sole first-to-file status for Ruxolitinib drug Application for Ruxolitinib Extended-Release Tablets with respect to applicable patents listed I with the US FDA.
Granules India Share Price Rise Streak: price, valuation
Granules India Eyes 180-Day Exclusivity on Generic Ruxolitinib
Granules India eyes potential 180-day US exclusivity for Ruxolitinib ER
Granules India plans ?2k cr investment to drive growth
Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.
Granules India files Paragraph IV certification for Ruxolitinib Extended-Release Tablets
Granules India plans ?2,000 crore investment to drive growth in complex generics, oncology, and peptide C
Granules India incorporates wholly owned subsidiary in Brazil
Granules India Share Price Fall Streak after 4.58% drop